Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has not responded to other treatments (or no standard treatment exists).
- Your tumor can be measured on scans (like CT or MRI).
- You are in generally good health (ECOG score 0 or 1, meaning you can do daily activities).
- Your blood counts, kidney function, and liver function are within certain ranges.
- You have no uncontrolled infections or conditions that require strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This trial tests adding natural killer (NK) cells to your usual maintenance treatment for advanced solid tumors. NK cells are a type of immune cell that may help your body fight cancer more effectively and delay the cancer from growing.
This trial tests a new immune cell therapy called NK521 for people with advanced solid tumors like liver or ovarian cancer that have not responded to standard treatment. The therapy may be given as an infusion or into the belly (for those with fluid buildup containing cancer cells).
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.